Literature DB >> 1299472

Assessing the needs and quality of life of patients with HIV infection: development of the HIV Overview of Problems-Evaluation System (HOPES).

C A Schag1, P A Ganz, B Kahn, L Petersen.   

Abstract

OBJECTIVE: To develop and evaluate the psychometric properties (reliability, validity etc.) of a comprehensive Quality of Life (QOL) tool, for patients infected with the human immunodeficiency virus (HIV), that was adapted from a previously validated cancer tool.
DESIGN: Cross-sectional, patient completed written surveys and interviews.
SETTING: The Medical Centers serving HIV infected patients in the Los Angeles community including UCLA, community physicians, Veterans Affairs Medical Centers, and a County hospital: and additional data contributed from Johns Hopkins University Medical Center CMV Retinitis Clinic. PATIENTS: Patients (n = 318) with HIV infection including asymptomatic (37%), ARC (20%), AIDS (25%) and AIDS with Cancer (18%) receiving health services at one of the above sites. MEASUREMENTS: The patients self-administered the newly developed instrument, the HOPES (HIV Overview of Problems-Evaluation System), other QOL related tools including the Medical Outcomes Study instrument adapted for HIV (MOS-HIV) the Profile of Mood States (POMS), the Perceived Adjustment to Chronic Illness Scale (PACIS), and the Physical Activity Scale (PAS). Brief interview to assess the Karnofsky Performance Status Score (KPS). Measured sociodemographic characteristics included age, sex, race, HIV risk factor, education etc. Assessed medical history, current medications, HIV clinical classification. MAIN
RESULTS: The sociodemographic and medical characteristics of the sample resemble those of the general population with HIV infection in this geographic area: 96% male, 28% nonwhite, 84% homosexual contact as risk factor, 75% receiving antiretroviral therapy. The adaptation of the cancer QOL instrument to HIV appears to have face and content validity according to patients and health professionals who care for HIV infected patients. Analyses of the psychometric properties found that the HOPES has a similar structure to its parent instrument following factor analyses which results in five summary scales representing the Physical, Psychosocial, Medical Interaction, Sexual and Significant Other/Partners domains in addition to a Global Score. Internal consistency of 35 subscales is high with a mean alpha coefficient of 0.82. Correlations of the HOPES summary scales with other QOL instruments are in the predicted directions. Comparing patients within the HIV clinical diagnostic categories on the HOPES Global, Physical, and Psychosocial Summary Scales indicates that Asymptomatic Patients have better QOL than symptomatic patients. This finding is also found in the other QOL instruments which provides evidence of construct validity.
CONCLUSIONS: The HOPES is an excellent tool for identifying the problems and needs of patients with HIV infection and for assessing their quality of life. It is reliable, valid and acceptable to patients. The tool may be especially useful in developing a normative data base.

Entities:  

Mesh:

Year:  1992        PMID: 1299472     DOI: 10.1007/bf00704434

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  37 in total

Review 1.  Quality of life: what is it? How should it be measured?

Authors:  N K Aaronson
Journal:  Oncology (Williston Park)       Date:  1988-05       Impact factor: 2.990

2.  Assessing problems of cancer patients: psychometric properties of the cancer inventory of problem situations.

Authors:  C A Schag; R L Heinrich; R L Aadland; P A Ganz
Journal:  Health Psychol       Date:  1990       Impact factor: 4.267

3.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

4.  Measuring quality of life: risks and benefits.

Authors:  H Schipper; M Levitt
Journal:  Cancer Treat Rep       Date:  1985-10

5.  Methodology in behavioral and psychosocial cancer research. Conceptualizing disease impact and treatment outcomes.

Authors:  J E Ware
Journal:  Cancer       Date:  1984-05-15       Impact factor: 6.860

6.  Living with cancer: the Cancer Inventory of Problem Situations.

Authors:  R L Heinrich; C C Schag; P A Ganz
Journal:  J Clin Psychol       Date:  1984-07

7.  Quality of life as a function of HIV classification.

Authors:  D Ragsdale; J R Morrow
Journal:  Nurs Res       Date:  1990 Nov-Dec       Impact factor: 2.381

Review 8.  Development of a comprehensive quality of life measurement tool: CARES.

Authors:  C A Schag; R L Heinrich
Journal:  Oncology (Williston Park)       Date:  1990-05       Impact factor: 2.990

9.  Describing the health-related quality of life impact of HIV infection: findings from a study using the HIV Overview of Problems--Evaluation System (HOPES).

Authors:  P A Ganz; C A Coscarelli Schag; B Kahn; L Petersen; K Hirji
Journal:  Qual Life Res       Date:  1993-04       Impact factor: 4.147

10.  Psychological factors in the prognosis of malignant melanoma: a prospective study.

Authors:  G N Rogentine; D P van Kammen; B H Fox; J P Docherty; J E Rosenblatt; S C Boyd; W E Bunney
Journal:  Psychosom Med       Date:  1979-12       Impact factor: 4.312

View more
  26 in total

1.  Psychometric evaluation of the functional assessment of HIV Infection (FAHI) questionnaire and its usefulness in clinical trials.

Authors:  Muriel Viala-Danten; Dominique Dubois; Hélène Gilet; Silas Martin; Katrien Peeters; David Cella
Journal:  Qual Life Res       Date:  2010-05-28       Impact factor: 4.147

2.  The effect of diagnosis with HIV infection on health-related quality of Life.

Authors:  Shyoko Honiden; Vandana Sundaram; Robert F Nease; Mark Holodniy; Laura C Lazzeroni; Andrew Zolopa; Douglas K Owens
Journal:  Qual Life Res       Date:  2006-02       Impact factor: 4.147

Review 3.  A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials.

Authors:  Darren J Clayson; Diane J Wild; Paul Quarterman; Isabelle Duprat-Lomon; Maria Kubin; Stephen Joel Coons
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Two approaches to measuring quality of life in the HIV/AIDS population: HAT-QoL and MOS-HIV.

Authors:  W C Holmes; J A Shea
Journal:  Qual Life Res       Date:  1999-09       Impact factor: 4.147

5.  Describing the health-related quality of life impact of HIV infection: findings from a study using the HIV Overview of Problems--Evaluation System (HOPES).

Authors:  P A Ganz; C A Coscarelli Schag; B Kahn; L Petersen; K Hirji
Journal:  Qual Life Res       Date:  1993-04       Impact factor: 4.147

6.  Quality of life of HIV-infected patients: psychometric properties and validation of the German version of the MQOL-HIV.

Authors:  G Kemmler; B Schmied; A Shetty-Lee; R Zangerle; H Hinterhuber; G Schüssler; B Mumelter
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

7.  Development and validation of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument.

Authors:  D F Cella; N L McCain; A H Peterman; F Mo; D Wolen
Journal:  Qual Life Res       Date:  1996-08       Impact factor: 4.147

8.  The assessment of mood at workplace - psychometric analyses of the revised Profile of Mood States (POMS) questionnaire.

Authors:  Matthias Morfeld; Corinna Petersen; Anja Krüger-Bödeker; Sylvia von Mackensen; Monika Bullinger
Journal:  Psychosoc Med       Date:  2007-05-10

9.  How do existing HIV-specific instruments measure up? Evaluating the ability of instruments to describe disability experienced by adults living with HIV.

Authors:  Kelly K O'Brien; Ahmed M Bayoumi; Carol Strike; Nancy L Young; Kenneth King; Aileen M Davis
Journal:  Health Qual Life Outcomes       Date:  2010-08-19       Impact factor: 3.186

10.  Comparing the performance of the EQ-5D and SF-6D when measuring the benefits of alleviating knee pain.

Authors:  Garry R Barton; Tracey H Sach; Anthony J Avery; Michael Doherty; Claire Jenkinson; Kenneth R Muir
Journal:  Cost Eff Resour Alloc       Date:  2009-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.